期刊文献+

胰腺癌诊疗的研究现状 被引量:12

Current status of diagnosis and treatment of pancreatic cancer
下载PDF
导出
摘要 胰腺癌是目前恶性程度极高的肿瘤之一,该病起病隐匿、发展迅速、病死率高。临床上早期诊断困难,治疗效果不佳。近年来,新型肿瘤标志物不断被发现,影像学检查不断发展提高了其诊断率,同时,治疗手段不断革新,延长了患者生存时间。本文就胰腺癌诊断和治疗的研究现状作一概述。 Pancreatic cancer is one of the most highly malignant tumors,whose clinical symptoms are insidious,progression is quick and mortality is high. It is difficult to detect early,the treatment is poor. In recent years,new tumor markers have been found and the continuous development of imaging studies improves the diagnostic rate,while treatment continues to innovate and extend the survival time of patients. This article was a review of the current status of the diagnosis and treatment of pancreatic cancer.
作者 高攀 朱祖安
出处 《胃肠病学和肝病学杂志》 CAS 2018年第1期17-21,共5页 Chinese Journal of Gastroenterology and Hepatology
关键词 胰腺癌 诊断 治疗 Pancreatic cancer Diagnosis Treatment
  • 相关文献

参考文献4

二级参考文献20

  • 1BURRIS H A, MOORE M J, ANDERSEN J, et al. Improvements in survival and clinical benefit with gemcitabine as first - line therapy for patients with advanced pancreas cancer: a randomized trial[ J]. J Clin Oncol, 1997,15 ( 6 ) : 2403 - 2413.
  • 2MOORE M J, GOLDSTEIN D, HAMM J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pan- creatic cancer: a phase Ⅲ trial of the National Cancer Institute of Canada Clinical Trials Group[J]. J Clin Oncol, 2007, 25(15) : 1960 -1966.
  • 3PARMAR M K, TORRI V, STEVART L, et al. Extracting summary statistics to perform Meta - analysis of the published literature for survival endpoint [ J ]. Stat Med, 1998,17 ( 24 ) : 2815 - 2834.
  • 4LIM J Y, CHO J H, LEE S J, et al. Gemcitabine combined with capecitabine compared to gemcitabine with or without Erlotinib as first -line chemotherapy in patients with advanced pancreatic cancer [J]. Cancer Res Treat, 2015, 47(2): 266-273.
  • 5WANG J P, WU C Y, YEH Y C, et al. Erlotinib is effective in pan- creatic cancer with epidermal growth factor receptor mutations : a ran- domized, open - label, prospective trial[ J ]. Oncotarget, 2015, 6 (20) : 18162 - 18173.
  • 6KHALIL M A, QIAO W, CARLSON P, et al. The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer [ J ]. Invest New Drugs, 2013, 31(5) : 1375 -1383.
  • 7KIM M A, LEE H S, LEE H E, et al. EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number[ J ]. Histopathology, 2008, 52 (6) : 738 - 746.
  • 8Rosty C,Goggins M.Early detection of pancreatic carcinoma[J].Hematol Oncol Clin North Am,2002,16(1):37-52.
  • 9Szajda SD,Waszkiewica N,et al.Carbohydrate markers of pancreatic cancer[J].Biochem Soc Trans,2011,39(1):340-343.
  • 10Yarnasaki H,Lkcd S,Okajima M,et al.Expression and localization of MUCI,MUC5AC and small intestinal mucin antigen in pancreatic tumor[J].Inr J Oncol,2004,24(1):107-113.

共引文献43

同被引文献104

引证文献12

二级引证文献43

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部